Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is an experimental combination cell therapy being investigated by Shanghai Changzheng Hospital. It involves the co-transplantation of allogeneic pancreatic islet cells and allogeneic human umbilical cord-derived mesenchymal stem cells (hUCMSCs) via portal vein infusion. The therapy is designed to treat patients with various forms of diabetes characterized by islet failure, including type 1 diabetes, advanced type 2 diabetes, and pancreatogenic diabetes. The hUCMSCs are intended to provide an immunomodulatory and cytoprotective environment to enhance the survival and functional integration of the transplanted islets, thereby restoring endogenous insulin production and improving glycemic control.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on allogeneic human umbilical cord mesenchymal stem cells + allogeneic pancreatic islets.